← Leaderboards
Andreas G Bader
Mirna Therapeutics, Inc.
$1,166,990
Attributed
$1,279,488
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $600K · FY2008–14$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$1,279,488 · 5
By mechanism
R43$1,054,492 · 4
R41$224,996 · 1
Top collaborators
- Aiming Yu1 shared
Others in their field
Top investigators on “Cancer Etiology”
- William J. Blot · Vanderbilt University$68,004,179
- Wei Zheng · Roswell Park Cancer Institute Corp$58,459,252
- Ulrike Peters · Fred Hutchinson Cancer Research Center$52,411,192
- Loic Le Marchand · University Of Hawaii At Manoa$41,925,802
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$41,621,676
- Brian E Henderson · University Of Southern California$40,297,112
Research focus
Cancer EtiologyPre-ClinicalCessation Of LifeMalignant NeoplasmsMicrornasCancer CellCancerousBaseMouse ModelCellsTumorResponseSurvival RateResistanceComplexPropertyOrganAnimal ModelOperative Surgical ProceduresPathway InteractionsMalignant Neoplasm Of LungGene ExpressionClinically RelevantDrug Kinetics
Grant awards (5)
A New MicroRNA-1291 Replacement Therapy for Pancreatic Cancer Disease$224,996
R41 · FY2014 · AA · contact PI
Systemic delivery of chitosan/miRNA nanoparticles to prostate tumors$299,999
R43 · FY2012 · CA · contact PI
Therapeutic miRNAs in combination with conventional chemotherapy$299,999
R43 · FY2012 · CA · contact PI
MicroRNA therapeutics for prostate cancer$282,967
R43 · FY2010 · CA · contact PI
Combination molecular therapeutics for lung cancer$171,527
R43 · FY2008 · CA · contact PI